An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia
- PMID: 15316165
- DOI: 10.1159/000079595
An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia
Abstract
Background and aim: Androgenetic alopecia (AGA) is undoubtedly the most common form of hair loss in males. It is a condition which may cause cosmetic and psychosocial problems in androgen-dependent cases. In this open, randomized and comparative study we evaluated the efficacy of oral finasteride and 5% topical minoxidil treatment for 12 months in 65 male patients with mild to severe AGA.
Methods: We randomly assigned 40 (61.53%) patients to receive 1 mg/day oral finasteride for 12 months, and 25 (38.47%) patients applied 5% topical minoxidil solution twice daily for 12 months.
Results: There were no significant differences between the 2 groups considering age, age of onset of hair loss, family history and type of hair loss (p > 0.05). In the clinical evaluation at the endpoint of treatment, the clinical cure rates (i.e. increased intensity of hair) were 80% (32/40) for the oral finasteride group and 52% (13/25) for the 5% topical minoxidil group. Encountered side effects were all mild, and there was no need to stop the treatment. In the group given oral finasteride, side effects were noted in 7 patients: 6 patients suffered from loss of libido, and 1 patient had an increase in other body hairs; irritation of the scalp was seen in 1 patient in the group administered 5% minoxidil. These adverse events disappeared as soon as the treatment was stopped. The laboratory data on both drug groups did not show any statistically or clinically significant intragroup changes from baseline values to the endpoint (p > 0.05), except the level of serum total testosterone which was increased, and free testosterone and serum prostate-specific antigen in the finasteride group which were statistically decreased from baseline values to the endpoint (p < 0.05).
Conclusion: In this comparative study of systemic finasteride and topical minoxidil, it was concluded that both drugs were effective and safe in the treatment of mild to severe AGA, although oral finasteride treatment was more effective (p < 0.05). Adverse events were not considered important either, and these side effects disappeared as soon as the treatment was stopped.
Similar articles
-
Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study.J Med Assoc Thai. 2012 Oct;95(10):1312-6. J Med Assoc Thai. 2012. PMID: 23193746 Clinical Trial.
-
A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.J Am Acad Dermatol. 2004 Apr;50(4):541-53. doi: 10.1016/j.jaad.2003.06.014. J Am Acad Dermatol. 2004. PMID: 15034503 Clinical Trial.
-
Randomized controlled trial on the efficacy and safety of the combination therapy of topical 0.1% finasteride - 5% Minoxidil in male androgenetic alopecia.Arch Dermatol Res. 2025 Apr 10;317(1):691. doi: 10.1007/s00403-025-04216-9. Arch Dermatol Res. 2025. PMID: 40208341 Clinical Trial.
-
Management of androgenetic alopecia.J Eur Acad Dermatol Venereol. 1999 May;12(3):205-14. J Eur Acad Dermatol Venereol. 1999. PMID: 10461639 Review.
-
Androgenetic alopecia: an evidence-based treatment update.Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5. Am J Clin Dermatol. 2014. PMID: 24848508 Review.
Cited by
-
Connarus semidecandrus Jack Exerts Anti-Alopecia Effects by Targeting 5α-Reductase Activity and an Intrinsic Apoptotic Pathway.Molecules. 2022 Jun 24;27(13):4086. doi: 10.3390/molecules27134086. Molecules. 2022. PMID: 35807332 Free PMC article.
-
Platycarya strobilacea S. et Z. Extract Has a High Antioxidant Capacity and Exhibits Hair Growth-promoting Effects in Male C57BL/6 Mice.Prev Nutr Food Sci. 2014 Sep;19(3):136-44. doi: 10.3746/pnf.2014.19.3.136. Prev Nutr Food Sci. 2014. PMID: 25320710 Free PMC article.
-
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.Adv Urol. 2012;2012:530121. doi: 10.1155/2012/530121. Epub 2011 Dec 25. Adv Urol. 2012. PMID: 22235201 Free PMC article.
-
Promotion of anagen, increased hair density and reduction of hair fall in a clinical setting following identification of FGF5-inhibiting compounds via a novel 2-stage process.Clin Cosmet Investig Dermatol. 2017 Feb 27;10:71-85. doi: 10.2147/CCID.S123401. eCollection 2017. Clin Cosmet Investig Dermatol. 2017. PMID: 28280377 Free PMC article.
-
Androgenetic Alopecia: Therapy Update.Drugs. 2023 Jun;83(8):701-715. doi: 10.1007/s40265-023-01880-x. Epub 2023 May 11. Drugs. 2023. PMID: 37166619 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous